slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 38,161-38,190
Pages 10,126
Rows per page 30
Component
38,161-38,190 of 303,780
18
The slide compares clinical outcomes (ORR, SD, CBR, PD) across four cohorts: two treatment groups and two historical control groups.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 2 hits
32
Swimmer plot showing patient IDs on y-axis and weeks on study on x-axis, with various clinical status markers.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 2 hits
33
Data shows a clear correlation between achieving MEC and better clinical outcomes in PDAC patients.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 2 hits
01
Features a photo of a child named Albie living with LAL-D.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Situation & Context2 hits
05
AstraZeneca | Investor Day Presentation Deck | 49 slidesAstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle2 hits
06
The slide uses iconography to represent key statistics about rare diseases.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle2 hits
09
The slide uses a horizontal bar chart format to represent clinical trial progress.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle2 hits
11
The slide uses a matrix-like layout to map drug candidates against biological targets and development status.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown2 hits
12
The slide uses a biological process flow to explain the therapeutic rationale for C5 inhibition.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown2 hits
13
The slide uses a timeline-like arrow to represent innovation and expansion into new indications.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown2 hits
14
The slide uses a waterfall-style comparison for pricing and a 2x2 grid for indication-specific growth strategies.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown2 hits
15
Includes clinical trial data (Study 301) and registry survival analysis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown2 hits
16
HLR = high-level results; gMG = generalised myasthenia gravis; MG-ADL = myasthenia gravis activities of daily living; QMG = quantitative myasthenia gravis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown2 hits
17
Includes three distinct data visualizations: a bar chart for median MG-ADL, a box plot for change from baseline, and a line chart for mean MG-ADL over time.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown2 hits
18
Includes 'Number at risk' table below the x-axis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown2 hits
19
The slide uses a Kaplan-Meier survival curve for HSCT-TMA and market sizing metrics for CSA-AKI.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown2 hits
20
The slide uses a combination of a timeline/map graphic and a bar chart to demonstrate market penetration and adoption speed.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet2 hits
21
Comparison of molecular weight (25 kDa vs 150 kDa) and administration method.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet2 hits
22
Includes clinical trial design diagram for Part A and Part B.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet2 hits
23
Includes a biological pathway diagram and a comparison of circulating concentrations.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet2 hits
24
The slide uses a horizontal timeline-like structure to compare three drug candidates (ALXN2040, ALXN2050, ALXN2080).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet2 hits
25
Includes FDA Breakthrough Designation callout and trial design diagrams.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet2 hits
27
The slide uses a pyramid to segment the market by patient need and product modality.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet2 hits
28
Uses a pictograph to represent patient population segments.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet2 hits
29
The chart shows a comparison of branded vs unbranded/off-label market size over time, and a pie chart showing patient source.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet2 hits
30
The slide uses a combination of scientific evidence (left) and market/trial status (right) to justify investment.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps2 hits
31
The slide uses a matrix layout to map drug assets against biological targets and development status (marketed, late-stage, early-stage, preclinical).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps2 hits
33
The slide uses a matrix-like layout to map drug assets against therapeutic areas and development status.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps2 hits
34
Includes a visual representation of the metabolic pathway and radiographic evidence of treatment efficacy.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps2 hits
35
The slide uses a Venn-style diagram to illustrate market expansion.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps2 hits